Atty. Dkt. No. 071949-2104

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the United States Patent and Trademark

Germaine Sarda

(Printed Name)

November 29, 2004

(Date of Deposit)

Office, Alexandria, Virginia on the date below.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Buechler, et al.

Title:

NOVEL METHODS FOR THE ASSAY

OF TROPONIN I AND T AND

COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES

FOR USE IN IMMUNOASSAYS

Appl. No.:

09/349,194

Filing Date:

06/07/1999

Examiner:

Gailene Gabel

Art Unit:

1641

TRANSMITTAL

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed please find the following:

[X] Appendix A: <u>Clean Copy</u> Text of the Claims as Amended in Submission Dated 07/07/2003 (14 Pages).

Respectfully submitted,

Date

November 29, 2004

FOLEY & LARDNER LLP

Customer Number: 30542

Telephone:

(858) 847-6722

Facsimile:

 ι_1^i

(858) 792-6773

By

Barry S. Wilson

Attorney for Applicant

Registration No. 39,431

Appendix A: <u>Clean Copy</u> Text of the Claims as Amended in Submission Dated July 7, 2003 (claims identified as" previously amended" were amended on July 7, 2003)

A Commence of the Commence of

1-84 (cancelled)

MO7.

85. (Previously pending) An assay for determining the presence or amount of a free and complexed cardiac specific isoform of troponin in a patient sample, said assay comprising: performing an immunoassay with an antibody which specifically binds said free cardiac specific isoform of troponin, and which specifically binds said cardiac specific isoform of troponin in a binary complex comprising one other troponin component selected from the group consisting of troponin I, troponin C and troponin T, and which specifically binds said cardiac specific isoform of troponin in a ternary complex comprising two other troponin components selected from the group consisting of troponin I, troponin C and troponin T; and detecting a signal from said immunoassay resulting from said antibody binding said free and complexed cardiac specific isoform of troponin, wherein said signal is at least a factor of two larger than a signal resulting from said antibody binding to an equal number of (i) free troponin components which are not said cardiac specific isoform of troponin; (ii) troponin complexes which do not comprise said cardiac specific isoform of troponin; or (iii) a combination of (i) and (ii), and wherein said signal is related to the presence or amount of said free and complexed cardiac specific isoform of troponin in said sample.

86. (Previously pending) An assay according to claim 85, wherein said patient sample is selected from the group consisting of a blood sample, a serum sample, and a plasma sample.

87. (Previously pending) An assay according to claim 85, wherein said signal from said immunoassay resulting from said antibody binding said free and complexed cardiac specific isoform of troponin is at least a factor of five greater than said signal resulting from said antibody binding to an equal number of (i) free troponin components which are not said cardiac specific isoform of troponin; (ii) troponin complexes which do not comprise said cardiac specific isoform of troponin; or (iii) a combination of (i) and (ii).

88. (Previously pending) An assay for determining the presence or amount of free and complexed cardiac specific isoforms of troponin in a patient sample, said assay comprising:

performing an immunoassay with an antibody which specifically binds to free cardiac specific troponin I and cardiac specific troponin T, and which specifically binds to cardiac specific troponin I and cardiac specific troponin T in a complex comprising at least one other troponin component selected from the group consisting of troponin I, troponin C and troponin T, and which specifically binds to cardiac specific troponin I and cardiac specific troponin T in a ternary complex comprising two other troponin components selected from the group consisting of troponin I, troponin C and troponin T; and

detecting a signal from said immunoassay resulting from said antibody binding said free and complexed cardiac specific isoforms of troponin, wherein said signal is at least a factor of two larger than a signal resulting from said antibody binding to an equal number of (i) free troponin components which are not said cardiac specific isoforms of troponin; (ii) troponin complexes which do not comprise said cardiac specific isoforms of troponin; or (iii) a combination of (i) and (ii), and wherein said signal is related to the presence or amount of said free and complexed cardiac specific isoforms of troponin in said sample.

- 89. (Previously pending) An assay according to claim 88, wherein said patient sample is selected from the group consisting of a blood sample, a serum sample, and a plasma sample.
- 90. (Previously pending) An assay according to claim 88, wherein said signal from said immunoassay resulting from said antibody binding said free and complexed cardiac specific isoforms of troponin is at least a factor of five greater than said signal resulting from said antibody binding to an equal number of (i) free troponin components which are not said cardiac specific isoforms of troponin; (ii) troponin complexes which do not comprise said cardiac specific isoforms of troponin; or (iii) a combination of (i) and (ii).
- 91. (Previously pending) An assay for determining the presence or amount of free and complexed cardiac specific troponin I in a patient sample, said assay comprising:

performing an immunoassay with an antibody which specifically binds to free cardiac specific troponin I, and which specifically binds to cardiac specific troponin I in a complex comprising at least one other troponin component selected from the group consisting of troponin C and troponin T, and which specifically binds to cardiac specific troponin I in a ternary complex comprising troponin C and troponin T; and

detecting a signal from said immunoassay resulting from said antibody binding said free and complexed cardiac specific troponin I, wherein said signal is at least a factor of two larger than a signal resulting from said antibody binding to an equal number of (i) free troponin components which are not said cardiac specific troponin I; (ii) troponin complexes which do not comprise said-cardiac specific troponin I; or (iii) a combination of (i) and (ii), and wherein said detectable signal is related to the presence or amount of said free and complexed cardiac specific troponin I in said sample.

- 92. (Previously pending) An assay according to claim 91, wherein said patient sample is selected from the group consisting of a blood sample, a serum sample, and a plasma sample.
- 93. (Previously pending) An assay according to claim 91, wherein said signal from said immunoassay resulting from said antibody binding said free and complexed cardiac specific troponin I is at least a factor of five greater than said signal resulting from said antibody binding to an equal number of (i) free troponin components which are not said cardiac specific troponin I; (ii) troponin complexes which do not comprise said cardiac specific troponin I; or (iii) a combination of (i) and (ii).
- 94. (Previously pending) An assay for determining the presence or amount of free and complexed cardiac specific troponin T in a patient sample, said assay comprising:

performing an immunoassay with an antibody which specifically binds to free cardiac specific troponin T, and which specifically binds to cardiac specific troponin T in a complex comprising at least one other troponin component selected from the group consisting of troponin C and troponin I, and which specifically binds to cardiac specific troponin T in a ternary complex comprising troponin C and troponin I; and

detecting a signal from said immunoassay resulting from said antibody binding said free and complexed cardiac specific troponin T, wherein said signal is at least a factor of two larger than a signal resulting from said antibody binding to an equal number of (i) free troponin components which are not said cardiac specific troponin T; (ii) troponin complexes which do not comprise said cardiac specific troponin T; or (iii) a combination of (i) and (ii), and wherein said detectable signal is related to the presence or amount of said free and complexed cardiac specific troponin T in said sample.

MOV

95. (Previously pending) An assay according to claim 94, wherein said patient sample is selected from the group consisting of a blood sample, a serum sample, and a plasma sample.

96. (Previously pending) An assay according to claim 94, wherein said signal from said immunoassay resulting from said antibody binding said free and complexed cardiac specific troponin T is at least a factor of five greater than said signal resulting from said antibody binding to an equal number of (i) free troponin components which are not said cardiac specific troponin T; (ii) troponin complexes which do not comprise said cardiac specific troponin T; or (iii) a combination of (i) and (ii).

97-101 (cancelled)

102. (Previously pending) An assay for determining the presence or amount of all free and complexed cardiac specific isoforms of troponin in a patient sample, said assay comprising:

performing an immunoassay with an antibody which specifically binds all free cardiac specific isoforms of troponin, and which specifically binds all cardiac specific isoforms of troponin in a complex comprising at least one other troponin component selected from the group consisting of troponin I, troponin C and troponin T, and which specifically binds all cardiac

specific isoforms of troponin in a ternary complex comprising two other troponin components selected from the group consisting of troponin I, troponin C and troponin T; and

detecting a signal from said immunoassay resulting from said antibody binding said free and complexed cardiac specific isoforms of troponin, wherein said signal is related to the presence or amount of all free and complexed cardiac specific isoforms of troponin in said sample.

103. (Previously pending) An assay according to claim 102, wherein said patient sample is selected from the group consisting of a blood sample, a serum sample, and a plasma sample.

104. (Previously pending) An assay according to claim 102, wherein said signal is approximately equal for equal amounts of all cardiac specific isoforms of troponin.

105. (Previously pending) An assay according to claim 102, wherein said signal is within 20% for equal amounts of all cardiac specific isoforms of troponin.

106. (Previously pending) An assay according to claim 102, wherein said signal is within a factor of 2 for equal amounts of all cardiac specific isoforms of troponin.

107-113 (cancelled)

114. (Previously pending) An assay for determining the presence or amount of a free and complexed cardiac specific isoform of troponin in a patient sample, said assay comprising:

performing an immunoassay with an antibody which specifically binds said free cardiac specific isoform of troponin, and which specifically binds said cardiac specific isoform of troponin in a complex comprising at least one other troponin component selected from the group consisting of troponin I, troponin C and troponin T, and which specifically binds said cardiac



FOLEY & LARDNER LLP ATTORNEYS AT LAW

11250 EL CAMINO REAL. SUITE 200 SAN DIEGO, CA 92130 P.O. BOX 80278 SAN DIEGO, CA 92138-0278 TELEPHONE: 858.847.6700 FACSIMILE; 858.792.6773 WWW.FOLEY.COM

FACSIMILE TRANSMISSION

Total # of Pages 16 (including this page)

TO:	PHONE #:	FAX #:
Ms. Diane Maggard United States Patent and Trademark Office Board of Patent Appeals and Interferences	,	571-273-0300

From: Barry S. Wilson

Date: November 29, 2004

Client/Matter No: 071949-2104

User ID No: 3067

MESSAGE:

De.

U.S. Patent Application No. 09/349,194

Our Ref.:

071949-2104

Per your request please find the enclosed documents:

Transmittal (1 pg.);

• Appendix A: Clean Copy Text of the Claims as Amended in Submission Dated 07/07/03 (14 pgs.).

If there are any problems with this transmission or if you have not received all of the pages, please call 858.847.6700.

Operator:	Time Sent:	Return Original To:
•		Germaine Sarda

CONFIDENTIALITY NOTICE: THE INFORMATION CONTAINED IN THIS FACSIMILE MESSAGE IS INTENDED ONLY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE DESIGNATED RECIPIENTS NAMED ABOVE. THIS MESSAGE MAY BE AN ATTORNEY-CLIENT COMMUNICATION, AND AS SUCH IS PRIVILEGED AND CONFIDENTIAL. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR ANY AGENT RESPONSIBLE FOR DELIVERING IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR, AND THAT ANY REVIEW, DISSEMINATION, DISTRIBUTION OR COPYING OF THIS MESSAGE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.